Alicia Gilsenan, PhD, FISPE

Vice President, Epidemiology
RTI Health Solutions
Research Triangle Park, North Carolina, United States

Disclosure information not submitted.

Presentation(s):

• SC-06 - Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development

  Friday, August 22, 2025
  9:00 AM - 12:30 PM ET

• 4C-06 - Evolution of Drug Initiation Patterns and Clinical Characteristics of New Users of Dapagliflozin in the United States up to 10 Years After Approval to Treat Type 2 Diabetes

  Monday, August 25, 2025
  5:30 PM - 5:45 PM ET

• 5C-02 - Quantitative Bias Analysis to Assess Impact of Outcome Misclassification in a Claims-based COVID-19 Vaccine Safety Study in the US

  Tuesday, August 26, 2025
  8:45 AM - 9:00 AM ET

• 5C-04 - An Observational Postauthorization Safety Study to Assess Adverse Events of Special Interest in Recipients of Ad26.COV2.S in the United States

  Tuesday, August 26, 2025
  9:15 AM - 9:30 AM ET

• 5C-06 - Incidence Rates of Myocarditis/Pericarditis after Pfizer-BioNTech COVID-19 Vaccine in the United States: Interim Results From a Postapproval Safety Study, Primary Series Analysis

  Tuesday, August 26, 2025
  9:45 AM - 10:00 AM ET